High-yield points
- The basics:
- WHO grade 1, circumscribed, the most common childhood CNS tumor.
- About 60% are cerebellar .
- Imaging: a cyst with an enhancing mural nodule. The nodule is the tumor; an enhancing cyst wall isn't necessarily tumor, and removing it didn't change outcome .
- Genetics:
- KIAA1549–BRAF fusion in 66% .
- Every tumor has a MAPK alteration (BRAF, FGFR1, NTRK2, NF1) .
- Surgery:
- Gross total resection is the key :
- Recurrence about 6–7% after total resection, vs. about 27–52% with residual.
- Many residuals regress spontaneously.
- Image for 8–10 years .
- Medical therapy:
- Unresectable or progressive tumors: chemotherapy (CV or TPCV; 5-year EFS about 40–50%) .
- BRAF V600: dabrafenib + trametinib beat chemotherapy .
- BRAF fusion or NF1: MEK or RAF inhibitors are active .
- Survival is excellent: OS over 95% at 8 years. Progression and morbidity, not death, are the main problems .
Landmark papers
- COG natural-history study (Wisoff et al., Neurosurgery 2011): 518 low-grade gliomas managed by surgery then observation. 5- and 8-year OS were 97% and 96% and PFS 80% and 78%, and gross total resection was the dominant predictor of PFS .
- Dabrafenib plus trametinib (Bouffet et al., N Engl J Med 2023): a randomized phase 2 trial (110 patients) vs carboplatin plus vincristine. Response was 47% vs 11% and median PFS 20.1 vs 7.4 months .
Pilocytic astrocytoma, formerly juvenile pilocytic astrocytoma, is a WHO grade 1, well-circumscribed, often cystic, slow-growing tumor . It is the most common CNS tumor of children and adolescents aged 5–19 . Pilocytic astrocytoma is essentially a single-pathway (MAPK) disease . Where it can be completely removed, surgery is curative. Unresectable midline tumors behave as a chronic disease, managed with chemotherapy and, increasingly, targeted MAPK inhibitors .
Classification and genetics
- WHO 2021: a circumscribed astrocytic glioma, alongside pleomorphic xanthoastrocytoma, SEGA and the new "high-grade astrocytoma with piloid features." The key genes listed are KIAA1549–BRAF, BRAF and NF1 .
- KIAA1549–BRAF fusion:
- A tandem duplication at 7q34 that yields a constitutively active BRAF kinase.
- Found in 66% of pilocytic astrocytomas, and in none of 244 higher-grade astrocytomas. That makes it useful both diagnostically and as a drug target .
- The whole MAPK pathway:
- Whole-genome sequencing found MAPK pathway alterations in every tumor, with no other significant mutations :
- BRAF fusions and other BRAF changes.
- FGFR1 and PTPN11 mutations, and NTRK2 fusions, in non-cerebellar tumors.
- NF1: NF1-associated tumors are a distinct, treatment-responsive group (see below) .
- BRAF V600E: less common, and associated with lower response to standard chemotherapy .
Presentation and imaging
- Sites:
- The cerebellum in about 60% of cases.
- The optic nerve, chiasm and tract are the other typical location .
- Classic MRI: "cyst with a mural nodule" :
- The solid nodule is T2/FLAIR hyperintense and enhances.
- The cyst fluid is slightly hyperintense to CSF and does not suppress on FLAIR.
- The cyst wall occasionally enhances, but that doesn't necessarily mean tumor, and removing the cyst wall did not affect outcome.
- Differential diagnosis of a cyst with mural nodule: hemangioblastoma, ganglioglioma, pleomorphic xanthoastrocytoma, desmoplastic infantile ganglioglioma .
Surgery and outcome
- Gross total resection is the main predictor:
- COG natural-history study (518 low-grade gliomas, surgery then observation) :
- Survival: 5- and 8-year OS 97% and 96%, and PFS 80% and 78%.
- On multivariate analysis, gross total resection was the dominant predictor of PFS.
- With limited residual tumor, 56% were free of progression at 5 years.
- Cerebellar tumors:
- Ogiwara (101 children, mean follow-up 18.4 years) :
- Recurrence: 5.9% after confirmed total resection vs. 52% with residual tumor.
- 10-year survival was 100%.
- Residual tumors: about half regressed spontaneously (32%) or stopped growing (16%).
- Timing: 96.6% of recurrences came within 8 years.
- Follow-up: image for 8–10 years.
- Due-Tønnessen (110 children, 1960–2001) :
- After total resection, recurrence was 7%.
- After subtotal resection, 27% of residual tumors grew, but 14 of 16 residuals regressed on recent MRI.
- Survival: 90% at 5 years and 85% at 25 years. Brainstem infiltration predicted worse survival.
- Reoperation (Kameda-Smith, 200 cerebellar tumors) :
- Initial gross total resection: 74.5%.
- Reoperation: 31 children had a second resection after a mean of 22.9 months.
- Cost: the multiple-operation group had more complications, including endocrinopathy.
- Practical rule: observe small residuals that would be risky to chase. Re-resect when growth makes that safe .
- Brainstem tumors (28 children) :
- 5-year PFS: 74% after GTR or resection leaving only linear enhancement, vs. 19% with solid residual.
- Overall: all patients were alive at last follow-up.
- Deficits: new postoperative deficits were common, and persisted in 6.
- Leptomeningeal dissemination (58 pooled cases):
- Overall survival: about half were alive at 5 years (5-year OS 55.5%).
- Chemotherapy and radiotherapy were both active against it .
Adjuvant and medical therapy (unresectable or progressive tumors)
- Chemotherapy (COG, children under 10) :
- 5-year EFS: carboplatin + vincristine (CV) 39% vs. TPCV 52%. The log-rank difference was not significant, though cure-model analysis favored TPCV.
- Worse outcome: younger age, tumor larger than 3 cm², and thalamic location.
- Choosing a regimen: toxicity influences the choice.
- MEK inhibition (selumetinib) :
- Recurrent pilocytic astrocytoma with a KIAA1549–BRAF fusion or V600E: 36% sustained partial response.
- NF1-associated low-grade glioma: 40% partial response.
- Next step: this led to COG phase 3 trials against chemotherapy.
- BRAF V600 tumors: dabrafenib + trametinib, first line :
- Randomized phase 2 (110 patients), vs. carboplatin + vincristine:
- Response 47% vs. 11%.
- Median PFS 20.1 vs. 7.4 months.
- Grade 3 or higher toxicity 47% vs. 94%.
- Type II RAF inhibitor (tovorafenib) in relapsed or refractory BRAF-altered pediatric LGG :
- Response: 67% by RANO-HGG criteria, or 51% by RAPNO.
- Side effects: hair color change is common.
- Radiotherapy: generally reserved for older children because of late effects. Chemotherapy was preferred in children under 10 when RT was considered high risk to development .
Related topics
- Optic Pathway Gliomas: pilocytic tumors of the visual pathway.
- Supratentorial Low-Grade Glioma: other pediatric low-grade gliomas and glioneuronal tumors.
- Neurofibromatosis: NF1-associated low-grade glioma.
- Spinal Cord Gliomas: spinal pilocytic astrocytoma.
- SEGA: the other circumscribed astrocytic glioma.
- Low-Grade Gliomas of the Brainstem in Children: brainstem pilocytic tumors in depth.
- Posterior Fossa Tumor Resection: step-by-step procedure.
References
- Raz E, Zagzag D, Saba L, et al. Cyst with a mural nodule tumor of the brain. Cancer Imaging 2012;12(1):237–244. doi:10.1102/1470-7330.2012.0028. PMID 22935908. verified
- Fangusaro J, Onar-Thomas A, Young Poussaint T, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol 2019;20(7):1011–1022. doi:10.1016/S1470-2045(19)30277-330277-3). PMID 31151904. verified
- Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008;68(21):8673–8677. doi:10.1158/0008-5472.CAN-08-2097. PMID 18974108. verified
- Jones DT, Hutter B, Jäger N, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 2013;45(8):927–932. doi:10.1038/ng.2682. PMID 23817572. verified
- Bouffet E, Hansford JR, Garrè ML, et al. Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med 2023;389(12):1108–1120. doi:10.1056/NEJMoa2303815. PMID 37733309. verified
- Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231–1251. doi:10.1093/neuonc/noab106. PMID 34185076. verified
- Wisoff JH, Sanford RA, Heier LA, et al. Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children's Oncology Group. Neurosurgery 2011;68(6):1548–1554. doi:10.1227/NEU.0b013e318214a66e. PMID 21368693. verified
- Ogiwara H, Bowman RM, Tomita T. Long-term follow-up of pediatric benign cerebellar astrocytomas. Neurosurgery 2012;70(1):40–48. doi:10.1227/NEU.0b013e31822ff0ed. PMID 21808215. verified
- Due-Tønnessen BJ, Helseth E, Scheie D, et al. Long-term outcome after resection of benign cerebellar astrocytomas in children and young adults (0–19 years): report of 110 consecutive cases. Pediatr Neurosurg 2002;37(2):71–80. doi:10.1159/000065108. PMID 12145515. verified
- Kameda-Smith MM, Green K, Hutton DL, et al. The role of reoperation in pediatric cerebellar pilocytic astrocytoma. J Neurosurg Pediatr 2024;34(2):169–175. doi:10.3171/2024.2.PEDS23236. PMID 38759245. verified
- Kestle J, Townsend JJ, Brockmeyer DL, et al. Juvenile pilocytic astrocytoma of the brainstem in children. J Neurosurg 2004;101(1 Suppl):1–6. doi:10.3171/ped.2004.101.2.0001. PMID 16206964. verified
- Mazloom A, Hodges JC, Teh BS, et al. Outcome of patients with pilocytic astrocytoma and leptomeningeal dissemination. Int J Radiat Oncol Biol Phys 2012;84(2):350–354. doi:10.1016/j.ijrobp.2011.12.044. PMID 22401918. verified
- Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol 2012;30(21):2641–2647. doi:10.1200/JCO.2011.36.6054. PMID 22665535. verified
- Kilburn LB, Khuong-Quang DA, Hansford JR, et al. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med 2024;30(1):207–217. doi:10.1038/s41591-023-02668-y. PMID 37978284. verified
Verification (2026-11-11): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts. The imaging details (60% cerebellar, cyst signal, cyst-wall enhancement, outcome after cyst-wall removal) come from the open-access full text of reference 1 (PMC3458787). The WHO 2021 category and genes come from the full text of reference 6 (PMC8328013), read via a fetch agent.
Caveats:
- The WHO 2021 summary does not list a grade for pilocytic astrocytoma in its grade table. "Grade 1" comes from references 1 and 2.
- References 8 and 14 include all pediatric low-grade gliomas, not only pilocytic astrocytoma.
- References 9 and 10 report "benign cerebellar astrocytomas."
- The figure is an original schematic.